Information is an important part of any engagement or dispensation. However, when it processed from data collected from scientific research its value increases many folds. As one of the leading causes of death globally, cancer is increasingly becoming a popular research subject with many resources dedicated to understanding the disease and finding its cure. Availability of information on cancer, treatment and prevention is therefore crucial in the fight against cancer. Oncotarget; a weekly medical journal, has taken a front row seat in the fight against cancer by publishing peer-reviewed scientific research on several disciplines.
Open Access and Popularity
Oncotarget is one of the leading peer-reviewed medical journal published on a weekly basis. The researches published in the journal are carried out by highly qualified scientists committed to advancing knowledge on the numerous disciplines covered by the journal. The multidisciplinary nature of the articles published in the journal under the sponsorship of Gordon Research Conference has played a key role in the popularity of the journal beyond scientific cycles. The journal is published by Impact Journals and uses an open model for its online versions. This has played a key role in its popularity including its impressive impact factor and Scopus/JSR ranking.
With over ten thousand citations since its establishment in 2010, Oncotarget offers very constructive researches on the various disciplines beyond oncology. Readers can access free insightful research-based information on cardiology, cell biology, neuroscience, cancer and molecular biology among other disciplines. The journal is committed towards ensuring that these researches achieve the desired impact. Additionally, Oncotarget seeks to bridge the gap between various biomedical science fields by offering a collaborative, open access platform for interaction. View Mikhail’s profile on Google Scholar
Oncotarget has a highly qualified editorial team made up of professionals with impeccable career and education profiles. The individuals have years of experience working in various positions including research scientists and professors. Mikhail Blagosklonny, its current editor-in-chief is a seasoned scholar and research scientists with experience as a professor and researcher in cancer. His is especially interested in anti-aging therapy as a cancer treatment option. These individuals combine their wealth of knowledge and experience to credible peer-reviews, which have played a key role in the journal’s popularity.